A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg

• Status: Completed
• Trial end date: 2019-03-13
• Target enrollment: 0
• Participant gender: Female

Summary

This study will assess the relationship between fulvestrant dose and efficacy in postmenopausal women with oestrogen receptor positive advanced breast cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Estradiol; Fulvestrant

Criteria

Inclusion Criteria:

• Breast Cancer has continued to grow after having received treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor.

• Requiring hormonal treatment.

• Postmenopausal women (woman who has stopped having menstrual periods)

Exclusion Criteria:

• Treatment with more than one previous regimen of systemic anticancer therapy other than endocrine therapy for advanced BC.

• Treatment with more than one previous regimen of endocrine therapy for advanced BC.

• An existing condition that prevents compliance.